Chelation therapy for treatment of systemic intoxication with uranium: A review

Abstract

Elevated levels of naturally occurring uranium have been found in small geographic areas throughout the world. Exposure of the general public to uranium is most often by the ingestion of food and water containing natural uranium from the hydrogeological environment, but this likelihood is remote. However, the risk is increased in regions where uranium is mined, milled, processed and/or fabricated as well as in the vicinity of former battlefields where depleted uranium munitions were deployed. Exposure in such cases is by the inhalation route. Internalized uranium is a long-term hazard the toxicity of which depends upon the dose and the dose rate as well as other parameters such as the chemical form and site of deposition of the uranium and the physiology of the host. The radiological toxicity and the chemical toxicity of uranium and its compounds are responsible for kidney damage and lung cancer. The vulnerable groups are the very young and the very old, individuals predisposed to hypertension or osteoporosis and individuals with chronic kidney disease. Those subject to long-term exposure from internalized uranium are a greater risk for the long-term implications. The accumulation of uranium may be mitigated by decreasing its absorption, distribution and deposition and increasing its elimination with chelating agents. The formation of soluble chelates may enhance the mobilization of uranium deposited in tissue and expedite its transport to and elimination from the renal system. The focus of this review is on the use of chelating agents to enhance decorporation of uranium thereby reducing the risk of intoxication.

Metal Chelation Therapy and Parkinson’s Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs

“…Metal chelation therapy involves the use of a chelating agent (CA), i.e., a molecule which forms stable coordination complexes with the target metal ion. Once administered to the patient, the CA acts as a scavenger removing the metal from its stores and favouring its decorporation from the body [69]. An efficient CA should be orally active and have a low cost, and both the ligand and the complexes formed in vivo should possess suitable hydrophilicity/hydrophobicity, and no redox activity [70].…”

Differential protein expression in metallothionein protection from depleted uranium-induced nephrotoxicity

“…For the treatment of DU intoxication, scholars mainly focused on DU decorporation in the body using synthetic chelating agents, and a series of agents have been developed910111213. However, there are few drugs with low toxicity that are highly effective in promoting the excretion of DU.…”

Nanomedicine-based disulfiram and metal ion co-delivery strategies for cancer treatment

“…MCT employs a chelating agent (CA) as a scavenger, which binds to excessive metals at the lesion site and forms stable ligand complexes with target metal ions. This facilitates the elimination of bound chelated metals from the body ( Šömen Joksić and Katz, 2015 ). In cancer treatment, tumor tissues exhibit slightly higher levels of copper compared to normal tissues, and diethyldithiocarbamate (DDC) or dithiocarbamate (or ester) (DTC) ( Fig.…”